Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.54 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5906832 | 1.00 | PPARG (0.54) | PPARGGPR34PPARAGPR132MME | |
| SCHEMBL5906830 | 0.87 | NPR3 (0.52) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL5906686 | 0.86 | MME (0.50) | PPARGPPARAMMEACECPA1 | |
| SCHEMBL5906688 | 0.86 | MME (0.50) | PPARGPPARAMMEACECPA1 | |
| SCHEMBL5906912 | 0.83 | PPARG (0.63) | PPARGGPR34GPR132 | |
| SCHEMBL5906908 | 0.83 | PPARG (0.63) | PPARGGPR34GPR132 | |
| SCHEMBL5906689 | 0.82 | GPR142 (0.47) | PPARGPPARA | |
| SCHEMBL5906691 | 0.82 | GPR142 (0.47) | PPARGPPARA | |
| SCHEMBL5906791 | 0.81 | CLK1 (0.47) | — | |
| SCHEMBL5906787 | 0.81 | CLK1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BAYER HEALTHCARE AG (DE) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BPHL, HRH4, HRH2 | PPARG 1055/4885GPR34 96/4885PPARA 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.